Initiаl Pоst оn Urinаry Trаct Infectiоns Urinary tract infections (UTIs) are one of the most common bacterial infections, especially in women. A UTI develops when bacteria enter the urinary tract and starts growing. The urinary tract is made up of the kidneys, ureters, bladder, and urethra. Most infections affect the bladder, which is known as cystitis. If the infection spreads to the kidneys, it becomes more serious and is called pyelonephritis. The most common cause of UTI is Escherichia coli (E. coli), a bacteria which normally lives in the gastrointestinal tract. Women are more likely to develop UTIs because their urethra is shorter, allowing bacteria to reach the bladder more quickly. Risk factors include sexual activity, pregnancy, postmenopausal changes, improper wiping techniques, urinary retention, catheter use, and a history of previous infections (Schmiemann et al., 2024). There is also some evidence that genetics can play a role. Certain people may have differences in their immune system or urinary tract lining that make it easier for bacteria to attach and cause infection. Symptoms can vary depending on how severe the infection is. Most people with a bladder infection experience burning with urination, urinary urgency, cloudy or strong-smelling urine, and lower abdominal discomfort. If the infection spreads to the kidneys, symptoms may include fever, flank pain, nausea, vomiting, and chills. In older adults, confusion may sometimes be the only noticeable symptom. During a physical assessment, providers often check for abdominal tenderness or costovertebral angle tenderness if kidney involvement is suspected. Diagnosis of a UTI is often based on symptoms and urinalysis. A urine dipstick test may show leukocyte esterase, nitrites, or white blood cells, indicating infection. For patients with recurrent urinary tract infections (defined as two infections in six months or three in one year), a urine culture is recommended to confirm the specific bacteria and guide treatment (Schiemann et al., 2024). Imaging such as ultrasound may be used if structural abnormalities are suspected. Current clinical practice guidelines emphasize avoiding unnecessary antibiotics and confirming infection before starting long-term preventive treatment. Treatment for uncomplicated UTIs typically includes short-course antibiotic therapy such as nitrofurantoin, trimethoprim-sulfamethoxazole (depending on resistance rates), or fosfomycin. These medications are very effective, but repeated antibiotic use can increase resistance. For patients with recurrent UTIs, daily or post-coital antibiotic prophylaxis may reduce recurrence, but it carries a risk of side effects and antibiotic resistance (Schiemann et al., 2024). Because of these concerns, non-antibiotic prevention methods are becoming more common. A recent systematic review found that methenamine may be an effective alternative for preventing recurrent UTIs and showed similar effectiveness to antibiotics without increasing adverse effects (Davidson et al.,2024). Other prevention strategies include increasing daily fluid intake, cranberry products, taking mannose supplements, and vaginal estrogen therapy for postmenopausal women (Schmiemann et al., 2024). These options support antimicrobial stewardship while still helping reduce recurrence. New therapies are also being studied. One recent clinical trial examined a CRISPR-enhanced bacteriophage therapy targeting E. coli in uncomplicated UTIs and showed promising early results (Kim et al., 2024). While this therapy is not yet standard practice, it may become an important option in the future as antibiotic resistance continues to rise. Overall, Urinary tract infections are very common but can significantly impact a person's quality of life, especially when they are recurrent. Proper diagnosis, evidence-based treatment, and individualized prevention strategies are important in reducing recurrence and preventing complications. As antibiotic resistance continues to grow, healthcare providers must balance effective treatment with responsible antibiotic use. References Davidson, S. M., Brown, J. N., Nance, C. B., & Townsend, M. L. (2024). Use of methenamine for urinary tract infection prophylaxis: Systematic review of recent evidence. International Urogynecology Journal. [https://doi.org/10.1007/s00192-024-05726-2](https://doi.org/10.1007/s00192-024-05726-2)Links to an external site. Kim, P., Sanchez, A. M., Penke, T. J. R., et al. (2024). Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): The randomized, open-label, first part of a two-part phase 2 trial. The Lancet Infectious Diseases. [https://doi.org/10.1016/S1473-3099(24)00424-9](https://doi.org/10.1016/S1473-3099%2824%2900424-9)Links to an external site. Schmiemann, G., Kranz, J., Mandraka, F., Schubert, S., Wagenlehner, F., & Gágyor, I. (2024). The diagnosis, treatment, and prevention of recurrent urinary tract infection. Deutsches Ärzteblatt International. [https://doi.org/10.3238/arztebl.m2024.0068](https://doi.org/10.3238/arztebl.m2024.0068)
Which type оf exаminаtiоn invоlves exаmining diseased tissue with a microscope?
True оr Fаlse: Humаns nоrmаlly have 22 pairs оf autosomes and 2 pairs of sex chromosomes.